Jurkat Reporter Cell Lines for Immunotherapy Drug Screening
WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening. Our platform includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc...
Continue ReadingKnowledge Library
Discovery and Characterization of Proteolysis Targeting Chimeras: Tissue Transglutaminase
Tissue transglutaminase (TG2) is a multifunctional enzyme activated in several pathological conditions, including cancer. WuXi AppTec recently contributed to a...
Continue Reading
One Stop Target-to-Hit Platform: PIK3CA–PIK3R1
Within the PI3K family, the heterodimer protein comprising the p110-α and p85-α catalytic/regulatory subunits (encoded by PIK3CA and PIK3R1) are...
Continue Reading One Stop Target-to-Hit Platform: Protein arginine methyltransferase 5 (PRMT5)
Protein arginine methyltransferase 5 (PRMT5) is an enzyme which plays an essential role in a wide range of cellular processes. ...
Continue Reading One Stop Target-to-Hit Platform: Cyclin-dependent kinase 2 (CDK2)
Cyclin-dependent kinase 2 (CDK2) and its respective cyclin E1 and cyclin A2 complexes are essential to driving abnormal growth processes...
Continue Reading One Stop Target-to-Hit Platform: Werner Syndrome Helicase (WRN)
Werner syndrome helicase (WRN) is a key drug target for cancers with microsatellite instability. To support the discovery of potent...
Continue Reading
Oncolytic Virus Platform
Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell...
Continue Reading
Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD)
WuXi AppTec scientists contributed to a study which identified a novel, indole-based, selective estrogen receptor degrader (SERD), designated LX-039. The authors...
Continue Reading
Evaluation Platform for Bispecific Antibodies
WuXi AppTec offers a full range of services to characterize bispecific antibodies and bispecific T cell engagers (BiTEs). Our comprehensive...
Continue Reading